Filing Analysis
Other SEC Filing
Filed Mar 11, 2026
LOW
Anixa Biosciences reported the results of its 2026 Annual Meeting of Stockholders held on March 10, 2026. Shareholders re-elected the board of directors, approved executive compensation on an advisory basis, and ratified the company's independent auditor.
Red Flags
- Significant shareholder opposition to executive compensation, with approximately 33% of the non-broker votes cast against the proposal.
- Notable 'Withheld' votes for directors Emily Gottschalk (1,886,761) and Lewis H. Titterton, Jr. (1,959,312), representing over 20% of the 'For' votes for those individuals.
Key Facts
- A total of 20,805,324 shares of common stock were represented at the meeting, out of 33,379,505 shares entitled to vote.
- Four directors (Dr. Amit Kumar, Dr. Arnold Baskies, Emily Gottschalk, and Lewis H. Titterton, Jr.) were re-elected to serve until the 2027 annual meeting.
- Executive compensation was approved with 6,025,247 votes for and 2,973,752 votes against.
- Haskell & White LLP was ratified as the independent auditor for the fiscal year ending October 31, 2026, with 20,426,524 votes in favor.
- The company filed an investor presentation as Exhibit 99.1 under Regulation FD disclosure.
Disclaimer: This analysis is generated by AI and is for informational purposes only.
It does not constitute financial advice, investment recommendations, or an offer to buy or sell securities.
Always review the original SEC filings and consult a financial advisor before making investment decisions.